What Analysts Expect from Aarti Pharmalabs Q4 FY26 Earnings

Aarti Pharmalabs Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Aarti Pharmalabs was listed on the National Stock Exchange (NSE) on 30-Jan-2023. Aarti Pharmalabs share has its face value of 5 per share, and its NSE symbol is AARTIPHARM. The company operates in the Healthcare sector and primarily belongs to the Pharmaceuticals industry.

Aarti Pharmalabs Q4 Results 2026 Preview

• Aarti Pharmalabs Q4 FY26 revenue is expected to be around Moderate Growth Expected, representing a 11-15% YoY increase compared to the same quarter last year.
• Profit After Tax, or PAT, is projected to rise 12-17% YoY.
• EBITDA to rise 13.50%.
• Aarti Pharmalabs is expected to show Moderate Growth Expected in its revenue. 

Click and Sign Up to Get Live Updates on Q4 Results

Aarti Pharmalabs Share Performance

• Over the past six months, Aarti Pharmalabs share price has 22% by 11-16% to 679.85.
• Moreover, over the past year, the stock has 38% by Up
• Despite this weak short-term performance, Aarti Pharmalabs stock has delivered a financially sound 175% return over the past 5 years.
• As of today, 09-03-2026, the Aarti Pharmalabs share price is trading at 679.85 per share.

Key Factors to Watch for Aarti Pharmalabs Q4 Results FY26

• Revenue Growth & Segment Performance – Focus on topline growth in the Pharmaceuticals industry within the Healthcare sector.
• Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
• Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
• Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
• Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.

About Aarti Pharmalabs

Aarti Pharmalabs is a pharmaceutical company specializing in APIs, intermediates, and specialty chemicals, offering custom synthesis and contract manufacturing services. It caters to global pharmaceutical markets with a diversified product portfolio across multiple therapeutic areas.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Final Thoughts

Aarti Pharmalabs is gear up to announce its Q4 FY26 results. Analysts expect 11-15% revenue growth, a 12-17% rise in PAT, and a 13.50% rise in EBITDA. Aarti Pharmalabs focuses on revenue growth from order execution, margin improvement, a strong order book, and management.

Stay informed with Univest blogs to get real-time updates on Aarti Pharmalabs Q4 results FY26. 

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Aadhar Housing Finance Gears Up for Q4 Reveal. Check Key Expectations Here

Aakash Exploration Services Gears Up for Q4 Reveal. Check Key Expectations Here

Aarey Drugs & Pharmaceuticals Gears Up for Q4 Reveal. Check Key Expectations Here

Aarnav Fashions Gears Up for Q4 Reveal. Check Key Expectations Here

Aaron Industries Gears Up for Q4 Reveal. Check Key Expectations Here

What Analysts Expect from Aarti Pharmalabs Q4 FY26 Earnings